Abstract-Although Smad3 is a key mediator of fibrosis, the functional role of Smad3 in hypertensive cardiovascular disease remains unclear. The present study tested the hypothesis that angiotensin II may activate the transforming growth factor-␤/Smad3 pathway to mediate hypertensive cardiac remodeling in Smad3 knockout (KO) and wild-type mice by subcutaneous angiotensin II infusion and in the primary culture of Smad3 KO cardiac fibroblasts. Fourteen days after angiotensin II infusion, both Smad3 KO and wild-type mice developed equal levels of high blood pressure. However, hypertensive cardiac fibrosis and inflammation were developed in Smad3 wild-type but not in Smad3 KO mice. This was demonstrated by the findings that mice lacking Smad3 were protected against a fall in left ventricular ejection fraction (PϽ0.05), an increase in left ventricular mass (PϽ0.05), and the development of cardiac fibrosis and inflammation, including upregulation of transforming growth factor-␤1, connective tissue growth factor, collagen I/III, ␣-smooth muscle actin, interleukin 1␤, tumor necrosis factor-␣, monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and an increase in macrophage and T-cell infiltration in left ventricular tissues (all PϽ0.01, respectively). Additional studies in vitro also revealed that angiotensin II-induced cardiac fibrosis and inflammation were prevented in Smad3 KO cardiac fibroblasts. Inactivation of both Smad3 and nuclear factor B/p65 signaling pathways was a key mechanism by which Smad3 KO mice were protected from angiotensin II-mediated hypertensive cardiac remodeling. In conclusion, Smad3 plays an essential role in hypertensive cardiac remodeling. Results from this study suggest that targeting Smad3 may be a novel therapeutic strategy for hypertensive cardiovascular disease. (Hypertension. 2010;55:1165-1171.)
H ypertensive cardiac remodeling, characterized by left ventricular (LV) hypertrophy and cardiac inflammation and fibrosis, is a major risk factor for cardiovascular morbidity and mortality and a leading cause of chronic heart failure. [1] [2] [3] It is generally agreed that activation of the reninangiotensin system plays an important pathophysiological role in chronic cardiovascular disease. This is supported by the finding that blockade of angiotensin II (Ang II) with either angiotensin-converting enzyme inhibitors or its type 1 receptor blockers significantly improves cardiac function and regresses cardiac remodeling in patients with hypertension and in animal models after myocardial infarction. 1, 3, 4 It is now clear that Ang II may act in both an autocrine and paracrine manner to activate a number of signaling pathways to mediate cardiac hypertrophy, inflammation, and fibrosis. This may involve mitogen-activated protein kinases, reactive oxygen species, receptor or nonreceptor-associated tyrosine kinases, and nuclear factor B (NF-B). 5 Increasing evidence has also shown that Ang II, via its Ang II type 1 receptor, upregulates transforming growth factor (TGF)-␤1 to induce cardiomyocyte hypertrophy, myofibroblast transition, and production of the extracellular matrix. 6 This is further confirmed by the finding that blockade of Ang II inhibits cardiac TGF-␤ expression and cardiac remodeling. 7, 8 It is now well accepted that TGF-␤1 is a key mediator in cardiac remodeling. 9 Thus, functional blockade of TGF-␤ attenuates cardiac remodeling and cardiac dysfunction in a number of animal models. 10 -12 A recent discovery of TGF-␤ signaling provides insights into a better understanding of TGF-␤1 in cardiac remodeling. It is now clear that TGF-␤1, after binding to its receptors, activates the downstream mediators, mainly Smad2 and Smad3, to exert its biological effects, which are negatively regulated by Smad7 via a negative feedback mechanism. 13 In the postinfarct heart, although expression of Smad2, 3, and 4 is increased, decreased Smad7 expression is also noted, 14, 15 suggesting the imbalance of TGF-␤ signaling during cardiac remodeling. The finding that blockade of Ang II with the Ang II type 1 receptor antagonist attenuates activation of Smads, and cardiac remodeling demonstrates the close link between the Ang II and TGF-␤/Smad signaling pathways. 16 It was further confirmed in recent studies that Ang II is capable of activating the TGF-␤/Smad signaling pathway to mediate vascular fibrosis via the extracellular signal-regulated kinase/ p38 mitogen-activated protein kinase-Smad cross-talk pathway, in addition to the classic TGF-␤-dependent mechanism. 17, 18 Furthermore, we also provided evidence for Smad3, not Smad2, as a key mediator of TGF-␤/Smad signaling in Ang II-induced vascular fibrosis. 18 A recent finding that mice lacking Smad3 were resistant to cardiac fibrosis and improved cardiac dysfunction after myocardiac infarction delineates an essential role for Smad3 in cardiac remodeling. 19 Because Ang II is able to activate Smad signaling to mediate vascular fibrosis, 17, 18 we, thus, hypothesized that Smad3 may be essential in hypertensive cardiac remodeling. This was examined in a mouse model of hypertension induced by Ang II in Smad3 knockout (KO) mice and in vitro in Smad3 KO cardiac fibroblasts.
Methods

Mouse Model of Ang II-Induced Hypertension
Smad3 KO and wild-type (WT) mice, congenic to the C57BL/6 strain, 20 were used in this study. Hypertensive cardiac remodeling was induced in genetically identical littermates of Smad3 KO and WT mice by subcutaneous infusion of Ang II at a dose of 1.46 mg/kg per day for 14 days via osmotic minipumps as described in the Methods section of the online Data Supplement (available at http://hyper.ahajournals.org).
Echocardiography
Echocardiography was performed in both Smad3 KO and WT mice before and at day 14 after Ang II infusion as described previously 21 and in the Methods section of the online Data Supplement.
Immunohistochemistry
Immunohistochemistry was performed in paraffin sections using a microwave-based antigen retrieval method, as described previously. 22 Antibodies and the detailed protocol were presented in the Methods section of the online Data Supplement.
Real-Time PCR
The ventricular total RNA was isolated using the RNeasy kit (Qiagen Inc). Expression of collagen I, III, ␣-smooth muscle actin (␣-SMA), TGF-␤1, connective tissue growth factor (CTGF), tumor necrosis factor-␣ (TNF-␣), interleukin (IL) 1␤, intercellular adhesion molecule 1, monocyte chemoattractant protein (MCP) 1, and GAPDH was detected by real-time PCR with the Opticon 2 Real-Time PCR detector (Bio-Rad) using the primers as described previously. 23, 24 The ratio against GAPDH for individual mRNAs was calculated and expressed as the meanϮSEM.
Western Blot Analysis
Proteins extracted from cultured cardiac fibroblasts were analyzed by Western blotting, as described previously. 24 The detailed protocol was described in the Methods section of the online Data Supplement.
In Vitro Study of Smad3 KO Cardiac Fibroblasts
Cardiac fibroblasts were isolated from both Smad3 WT and KO mice and characterized as described previously. 25 Cardiac fibroblasts at passage 3 were stimulated with Ang II (1 mol/L) as described in the Methods section of the online Data Supplement.
Statistical Analyses
Data obtained from this study are expressed as the meanϮSEM. Statistical analyses were performed using 1-way ANOVA followed by Newman-Keuls multiple comparison test from GraphPad Prism 4.0 (GraphPad Software, Inc). 
Results
Smad3 KO Mice Are Protected Against Ang II-Induced Cardiac Remodeling Histologically and Functionally
As shown in Figure S1A , Smad3 WT and KO mice treated with saline had normal systolic blood pressure. However, Ang II infusion resulted in an equal increase in high blood pressure in both Smad3 WT and KO mice, reaching the maximal levels at day 7 after Ang II infusion. Interestingly, cardiac dysfunction, including a significant decrease in LV ejection fraction and an increase in LV mass, was developed in Smad3 WT but not in Smad3 KO mice ( Figure S1B ). Histologically, although Smad3 WT mice developed focal inflammation and fibrosis within the myocardium and the perivascular area ( Figure S1C ), Smad3 KO mice exhibited a normal cardiac histology ( Figure S1C ).
Ang II-Induced Cardiac Fibrosis Is Prevented in Smad3 KO Mice
Ang II-induced cardiac fibrosis in Smad3 WT and KO mice at the mRNA and protein levels was examined by immunohistochemistry and quantitative real-time PCR. As shown in Figure 1A through 1D, compared with the saline-treated mice, Ang II infusion significantly increased collagen I and III mRNA and protein expression in LV tissues of Smad3 WT mice, particularly in the focal area with severe myocardium damage and in the perivascular area. In contrast, Ang IIinduced cardiac fibrosis was inhibited in Smad3 KO mice. Similarly, mice lacking Smad3 also attenuated Ang IIinduced upregulation of ␣-SMA mRNA expression ( Figure  1E ) and ␣-SMA ϩ myofibroblast accumulation (data not shown).
Mice Lacking Smad3 Are Protected From Ang II-Induced Cardiac Inflammation
Immunohistochemistry detected that no leukocytic infiltration was evident in the myocardium in both normal and saline-treated Smad3 WT and KO mice (data not shown). However, Ang II infusion resulted in a large number of leukocytes infiltrating the myocardium in Smad3 WT mice, primarily localizing to the damaged areas of cardiac tissues and resulting in a severe perivascular inflammation, as Ang II-upregulated mRNA expression of cardiac TNF-␣ and MCP-1 ( Figure 3C and 3D) , as well as IL-1␤ and intercellular adhesion molecule 1 ( Figure S2 ).
Loss of Smad3 Signaling and Inactivation of the NF-B Signaling Pathway Are Key Mechanisms by Which Smad3 KO Mice Are Protected From Ang II-Induced Hypertensive Remodeling
We then investigated the mechanisms by which Smad3 KO mice were protected against Ang II-mediated cardiac fibrosis and inflammation. As shown in Figures 4 and 5 , immunohistochemistry and real-time PCR revealed that Ang II infusion markedly upregulated cardiac TGF-␤1 and CTGF expressions in Smad3 WT mice (Figure 4 ), resulting in a strong activation of Smad2/3, as demonstrated by numerous nucleated phospho-Smad2/3 cells ( Figure 5A ). These changes were particularly intensified in the damaged cardiac tissues and the perivascular region ( Figures 4A,  4B , 5A, and 5C) but were absent in Ang II-infused Smad3 KO mice (Figures 4, 5A , and 5C). Additional study by immunohistochemistry also delineated that Ang II infusion caused a marked activation of NF-B signaling, as demonstrated by the increased nuclear localization of the phosphorylated NF-B/p65 subunit in the damaged cardiac tissues, including the perivascular region of Smad3 WT mice ( Figure 5B and 5D ). In contrast, Smad3 KO mice showed no significant NF-B/p65 activation in response to Ang II infusion ( Figure 5B and 5D) .
In Vitro Deletion of Smad3 in Cardiac Fibroblasts Inhibits Ang II-Induced Cardiac Inflammation and Fibrosis
Cardiac fibroblasts isolated from Smad3 WT and KO mice were stimulated with Ang II. Consistent with the in vivo findings, Western blot and real-time PCR showed that Ang II-induced expression of collagen I and ␣-SMA mRNA and protein expression was significantly increased in Smad3 WT but not in Smad3 KO cardiac fibroblasts ( Figure 6A and 6B) . This was associated with marked differentiation of cardiac fibroblasts into ␣-SMA ϩ myofibroblasts (55%) in Smad3 WT but not in Smad3 KO mice ( Figure S3) . Furthermore, the addition of Ang II was also able to upregulate TNF-␣, IL-1␤, and MCP-1 mRNA expression in Smad3 WT but not in Smad3 KO cardiac fibroblasts ( Figure 6B ). All of the results obtained in vitro again indicated that Smad3 signaling is essential for Ang II-induced cardiac fibrosis and inflammation.
Discussion
A growing body shows that Ang II may act as a growth factor to directly or indirectly (by stimulating TGF-␤1) promote cardiac remodeling and dysfunction. 6, 8 In the present study, we identified that Smad3 is essential for hypertensive cardiac remodeling induced by Ang II, because mice null for Smad3 were resistant to Ang II-mediated cardiac fibrosis and inflammation, despite hypertension. Loss of the TGF-␤/Smad3 and the NF-B signaling pathways may be mechanisms by which deletion of Smad3 prevents hypertensive cardiac remodeling in response to Ang II. Inhibition of Ang II-mediated cardiac fibrosis may be a key mechanism by which Smad3 KO mice were protected against hypertensive cardiac remodeling. This was supported by the findings that Ang II-induced cardiac fibrosis and cardiac dysfunction, such as a fall in LV ejection fraction and an increase in LV mass index, were inhibited in Smad3 KO mice. Furthermore, in vitro studies have also shown that Ang II (0.1 mol/L) and TGF-␤1 can induce cardiac fibroblasts to express ␣-SMA and differentiate into collagen-producing myofibroblasts to some degrees. 26, 27 In the present study, higher levels of ␣-SMA expression were induced in cardiac fibroblasts under a higher concentration of Ang II (1 mol/ L), which resulted in Ͼ55% of cardiac fibroblasts to differentiate into ␣-SMA ϩ myofibroblasts in Smad3 WT but not in Smad3 KO cardiac fibroblasts. This finding also demonstrated a critical role for Smad3 in Ang II-induced myofibroblast differentiation during cardiac remodeling, which is consistent with a known role for Smad3 but not Smad2 in TGF-␤ and Ang II-induced vascular and renal fibrosis in a dosage-dependent manner in vitro 17, 18, 24 and in vivo in postinfarcted cardiac remodeling. 19 Thus, loss of Smad3 signaling may be a central mechanism by which Smad3 KO mice were protected from Ang II-induced cardiac fibrosis.
In the present study, we also found that Smad3 is critical in Ang II-mediated cardiac inflammation. This was evidenced by the findings that Ang II-induced cardiac inflammation, particularly perivascular inflammation, was inhibited in Smad3 KO mice. Indeed, Ang II infusion resulted in a marked increase in perivascular CD45 ϩ leukocytes, F4/80 ϩ macrophages, and CD3 ϩ T cells. This was associated with upregulation of proinflammatory cytokines (IL-1␤ and TNF-␣), chemokine (MCP-1), and intercellular adhesion molecule 1 in cardiac tissues of Smad3 WT mice. In contrast, cardiac inflammation was absent in Smad3 KO mice, despite Ang II-induced hypertension. The resistance of Smad3 KO mice to Ang II-induced cardiac inflammation was consistent with the previous studies that showed that mice null for Smad3 inhibit inflammatory response in the postinfracted heart. 19 Although mechanisms whereby loss of Smad3 inhibits inflammation remain largely unclear, they may be associated with the inhibitory effect of TGF-␤/Smad3 on Ang IIinduced MCP-1 and NF-B-dependent inflammatory responses. 28, 29 It is known that Smad3 is critical for TGF-␤-induced MCP-1 expression during vascular inflammation 30 ; therefore, activation of cardiac Smad3 in response to Ang II and TGF-␤1 may contribute to an increase in macrophage infiltration in the hypertensive heart. This may be a mechanism whereby macrophage infiltration was inhibited in the hypertensive heart of Smad3 KO mice. Moreover, blockade of Ang II-induced NF-B activation may also be a signaling mechanism of suppressed cardiac inflammation in Smad3 KO mice. It is now well accepted that Ang II acts by stimulating the NF-B signaling pathway to mediate cardiovascular inflammation. 2,3,5,28, 29 We have also shown that inactivation of Smad2/3 by overexpressing Smad7 inhibits NF-B-dependent inflammatory response by inducing inhibitor of NF-B␣ expression under high Ang II disease conditions. 31, 32 In contrast, loss of Smad7 promotes Smad2/3 activation and renal inflammation. 33 Taken together, these findings suggest that the interaction between the TGF-␤/Smad and NF-B signaling pathways may be important in Ang II-induced cardiac inflammation.
Perspectives
Results from this study clearly demonstrate that Smad3 is essential for hypertensive cardiac remodeling. Smad3 may be a key mediator of downstream TGF-␤ signaling in chronic cardiovascular disease in response to Ang II and high blood pressure. Activation of Smad3 not only causes extracellular matrix synthesis by cardiovascular cells but also promotes cardiac inflammation, possibly via the Smad3-dependent MCP-1 mechanism. Findings that Smad3 KO mice were protected against Ang II-mediated cardiac fibrosis and inflammation suggest that targeting Smad3 may be a novel therapeutic strategy for hypertensive cardiovascular disease.
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Smad3 mediates cardiac inflammation and fibrosis in angiotensin II
Western Blot Analysis
Proteins extracted from cultured cardiac fibroblasts were analyzed by Western blotting as previously described [5] . After blocking with 5% non-fat milk, the membranes were incubated overnight at 4 o C with primary antibodies against collagen I and -SMA (Southern Biotech) and GAPDH (Chemicon Inc., Temecula, CA) and then were incubated with IRDyeTM800 conjugated secondary antibodies (Rockland Immunochemical Inc., Gilbertsville, PA) in dark for 1 hour at room temperature. Signals were scanned and visualized by Odyssey Infrared Imaging System (LiCor Inc., Lincoln, NE). The ratio of the protein interested was subjected to GAPDH and was densitometrically analyzed by Image J software (NIH, Bethsda, MD).
In vitro study of Smad3 KO cardiac fibroblasts Cardiac fibroblasts were isolated from both Smad3 WT and KO mice and were characterized as described previously [6] . Cardiac fibroblasts at passage 3 were stimulated with Ang II (1 M) for 6 hours (for mRNA expression) and 24 hours (for protein expression) for collagen I, -SMA, TNF, IL-1, and MCP-1 expression examined by both Western blot and real-time PCR analyses. The time selected for the study was determined by the preliminary time-dependent assays (hours 0, 1, 3, 6, 12, 24) with the findings that Ang II (1M) induced the peaked mRNA expression at 3-6 hours and protein expression at 24 hours.
Statistical analyses
Data obtained from this study are expressed as the mean ± SEM. Statistical analyses were performed using one-way analysis of variance (ANOVA) followed by Newman-Keuls Multiple Comparison Test from GraphPad Prism 4.0 (GraphPad Software, Inc. San Diego, CA). 
Results
